ArticleInternational journal of molecular sciences2017
Integrity and Quantity of Total Cell-Free DNA in the Diagnosis of Thyroid Cancer: Correlation with Cytological Classification.
Article in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Utility of Cell-Free DNA integrity index in differentiating malignant from benign lesions in indeterminate thyroid nodules.Endocrine · 2026Article
- Prospective observational study of cell-free DNA as a prognostic biomarker in COVID-19 and bacterial sepsis: COVSEP-study.Scientific reports · 2025Observational
- Clinical relevance of circulating biomarkers in breast cancer metastasis detection: "insights from liquid biopsy technology".Research in pharmaceutical sciences · 2025Article
- Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives.European journal of medical research · 2025Review
- Cell-free DNA as a potential diagnostic biomarker in academic stress: A case-control study in young adults.Saudi journal of biological sciences · 2024Article
- Plasma cell-free DNA as predictor of disease status in patients with differentiated thyroid cancer - a prospective study from a tertiary care institution.Frontiers in oncology · 2024Article
- Diagnostic value of combined detection of plasma cfDNA concentration and integrity in NSCLC.Lung cancer management · 2024Article
- Ampholytic ion-exchange magnetic beads: a promising tool for selecting short fragments in circulating cell-free DNA analysis.Frontiers in oncology · 2024Article
- Article
- Liquid Biopsies, Novel Approaches and Future Directions.Cancers · 2023Review
- Quantitative analysis of serum cell-free DNA as a predictive and prognostic marker in breast cancer patients.Frontiers in oncology · 2023Article
- Review
- Incidental discovery of acute myeloid leukemia during liquid biopsy of a lung cancer patient.Cold Spring Harbor molecular case studies · 2022Article
- Cell-Free DNA Variables including Gene Mutations in CA15-3 Normal Breast Cancer Reflect Prognosis.Disease markers · 2022Article
- Article
- Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer.International journal of molecular sciences · 2021Review
- Review
- Limited Clinical and Diagnostic Utility of Circulating Tumor DNA Detection in Patients with Early-Stage Well-Differentiated Thyroid Cancer: Comparison with Benign Thyroid Nodules and Healthy Individuals.Healthcare (Basel, Switzerland) · 2021Article
- Review
- Clinical Significance of Monitoring Circulating Free DNA and Plasma Heat Shock Protein 90alpha in Patients with Esophageal Squamous Cell Carcinoma.Cancer management and research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell-free DNA (cfDNA) quantity and quality in plasma has been investigated as a non-invasive biomarker in cancer. Previous studies have demonstrated increased cfDNA amount and length in different types of cancer with respect to healthy controls. The present study aims to test the hypothesis that the presence of longer DNA strands circulating in plasma can be considered a biomarker for tumor presence in thyroid cancer. We adopted a quantitative real-time PCR (qPCR) approach based on the quantification of two amplicons of different length (67 and 180 bp respectively) to evaluate the integrity index 180/67. Cell-free DNA quantity and integrity were higher in patients affected by nodular thyroid diseases than in healthy controls. Importantly, cfDNA integrity index was higher in patients with cytological diagnosis of thyroid carcinoma (Thy4/Thy5) than in subjects with benign nodules (Thy2). Therefore, cfDNA integrity index 180/67 is a suitable parameter for monitoring cfDNA fragmentation in thyroid cancer patients and a promising circulating biomarker in the diagnosis of thyroid nodules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.